![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CRUCELL AND UCB SIGN STAR LICENSE AGREEMENT
CRUCELL AND UCB SIGN STAR LICENSE AGREEMENT
September 8, 2006
Dutch biotechnology company Crucell N.V. announced that it has signed a STAR licensing agreement with UCB, a leading biopharmaceutical company with headquarters in Brussels, making UCB the first European STAR licensee. The agreement covers a 5-year non-exclusive STAR research license for the production of monoclonal antibodies. Yahoo Finance (http://biz.yahoo.com/iw/060907/0160775.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct